Journal
THERANOSTICS
Volume 5, Issue 9, Pages 985-994Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.11938
Keywords
aptamer; cell-SELEX; pancreatic ductal adenocarcinoma; molecular probe
Categories
Funding
- National Key Scientific Program of China [2011CB911000]
- NSFC [NSFC 2013CB932702, NSFC 21405041, NSFC 21221003, NSFC 21327009]
- China National Instrumentation Program [2011YQ03012412]
- National Institutes of Health [GM079359, CA133086]
- NATIONAL CANCER INSTITUTE [R01CA133086] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM079359] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC). Aptamer XQ-2d selectively binds to PL45 cells with a dissociation constant in the nanomolar range, as determined by its recognition of PL45 tumor cells in mice. Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%). Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
